For the past decade, ketamine, an N-methyl-D-aspartate receptor (NMDAr) antagonist, has
been considered a promising treatment for major depressive disorder (MDD). Unlike the …

Background The glutamatergic modulator ketamine has rapid antidepressant effects in
individuals with major depressive disorder and bipolar depression. Thus, modulating …

Non-competitive N-methyl-D-aspartate/glutamate receptor (NMDAR) antagonism has been
considered to play important roles in the pathophysiology of schizophrenia. In spite of …

Despite the rapid and sustained antidepressant effects of ketamine and its metabolites, their
underlying cellular and molecular mechanisms are not fully understood. Here, we …

Highlights•Ketamine's antidepressant effects in preclinical models are sexually different.•The
higher sensitivity of females to ketamine is modulated by hormonal fluctuations.•Ketamine …

Converging evidence suggests that a single sub-anesthetic dose of ketamine can produce
strong and rapid antidepressant effects in patients that do not respond to standard treatment …

Subanesthetic ketamine evokes rapid antidepressant effects in human patients that persist
long past ketamine's chemical half-life of~ 2 h. Ketamine's sustained antidepressant action …

Major depressive disorder negatively impacts the sensitivity and adaptability of the brain's
predictive coding framework. The current electroencephalography study into the …

Ketamine acts as a rapid clinical antidepressant at 25 min after injection with effects
sustained for 7 days. As dissociative effects emerging acutely after injection are not entirely …

The serendipitous discovery of ketamine's antidepressant effects represents one of the
major landmarks in neuropsychopharmacological research of the last 50 years. Ketamine …